6623 research outputs found
Sort by
Psoriasis-like skin inflammation is reduced in transgenic mice overexpressing inhibitory PAS domain protein （Inhibitory PAS domain protein過剰発現マウスでは乾癬様皮膚炎が減弱する）
Get PDF博士（医学）旭川医科大
Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer （リン酸化ビメンチンを標的とした大腸癌に対する腫瘍反応性ヘルパーT細胞応答に関する研究）
Get PDFColorectal cancer (CRC) patients with metastatic lesions have low 5-year survival rates. During metastasis, cancer cells often obtain unique characteristics such as epithelial-mesenchymal transition (EMT). Vimentin a biomarker contributes to EMT by changing cell shape and motility. Since abnormal phosphorylation is a hallmark of malignancy, targeting phosphorylated vimentin is a feasible approach for the treatment of metastatic tumors while sparing non-tumor cells. Recent evidence has revealed that both CD8 cytotoxic T lymphocytes (CTLs) and also CD4 helper T lymphocytes (HTLs) can distinguish post-translationally modified antigens from normal antigens. Here, we showed that the expression of phosphorylated vimentin was upregulated in metastatic sites of CRC. We also showed that a chemotherapeutic reagent augmented the expression of phosphorylated vimentin. The novel phosphorylated helper peptide epitopes from vimentin could elicit a sufficient T cell response. Notably, precursor lymphocytes that specifically reacted to these phosphorylated vimentin-derived peptides were detected in CRC patients. These results suggest that immunotherapy targeting phosphorylated vimentin could be promising for metastatic CRC patients
